LOAMU
BMRN icon

Lombard Odier Asset Management (USA)’s BioMarin Pharmaceuticals BMRN Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-22,600
Closed -$1.91M – 192
2019
Q4 		$1.91M Buy
+22,600
New +$1.71M 0.17% 141

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s BMRN Position: Q1 2020 in Review

Lombard Odier Asset Management (USA) sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2020, closing a stake of 22,600 shares — an estimated $1.91M sold.

Lombard Odier Asset Management (USA) first reported a position in BMRN in Q4 2019 and held it in 1 quarter. The position peaked at $1.91M in Q4 2019. 501 funds tracked by Wall St. Rank hold BMRN as of Q1 2020.

  • Lombard Odier Asset Management (USA) reported no remaining BioMarin Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 22,600 BioMarin Pharmaceuticals shares in Q1 2020, an estimated $1.91M.
  • Lombard Odier Asset Management (USA) first reported a position in BioMarin Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Lombard Odier Asset Management (USA)'s BioMarin Pharmaceuticals position peaked at $1.91M in Q4 2019.
  • 501 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2020.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q1 2020, filed 15 May 2020.